Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C VanCott

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Journal of Clinical Microbiology|May 8, 2003
Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapyRobert J O'Connell, Teresa M Merritt, Jennifer A Malia, et al.
AIDS Research and Human Retroviruses|February 15, 2001
HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodiesV R Polonis, M S De Souza, P Chanbancherd, et al.
AIDS Research and Human Retroviruses|December 31, 1998
HIV type 1 subtypes in Malaysia, determined with serologic assays: 1992-1996C Beyrer, T C Vancott, N K Peng, et al.
The Journal of Infectious Diseases|February 1, 1997
Mucosal immune responses in four distinct compartments of women infected with human immunodeficiency virus type 1: a comparison by site and correlation with clinical informationA W Artenstein, T C VanCott, K V Sitz, et al.
The Journal of Infectious Diseases|October 21, 1998
Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infectionL D Loomis-Price, J H Cox, J R Mascola, et al.
Nature Medicine|November 2, 2001
Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopesX Chen, G Scala, I Quinto, et al.
Plos One|November 17, 2010
Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adultsBruce K Brown, Josephine Cox, Anita Gillis, et al.
AIDS Research and Human Retroviruses|August 4, 2001
Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infectionJ H Kim, J R Mascola, S Ratto-Kim, et al.
AIDS Research and Human Retroviruses|September 20, 1996
Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assayJ R Mascola, M K Louder, S R Surman, et al.
Journal of Virology|April 10, 1999
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodiesJ R Mascola, M G Lewis, G Stiegler, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Journal of Clinical Microbiology|May 8, 2003
Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapyRobert J O'Connell, Teresa M Merritt, Jennifer A Malia, et al.
AIDS Research and Human Retroviruses|February 15, 2001
HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodiesV R Polonis, M S De Souza, P Chanbancherd, et al.
AIDS Research and Human Retroviruses|December 31, 1998
HIV type 1 subtypes in Malaysia, determined with serologic assays: 1992-1996C Beyrer, T C Vancott, N K Peng, et al.
The Journal of Infectious Diseases|February 1, 1997
Mucosal immune responses in four distinct compartments of women infected with human immunodeficiency virus type 1: a comparison by site and correlation with clinical informationA W Artenstein, T C VanCott, K V Sitz, et al.
The Journal of Infectious Diseases|October 21, 1998
Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infectionL D Loomis-Price, J H Cox, J R Mascola, et al.
Nature Medicine|November 2, 2001
Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopesX Chen, G Scala, I Quinto, et al.
Plos One|November 17, 2010
Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adultsBruce K Brown, Josephine Cox, Anita Gillis, et al.
AIDS Research and Human Retroviruses|August 4, 2001
Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infectionJ H Kim, J R Mascola, S Ratto-Kim, et al.
AIDS Research and Human Retroviruses|September 20, 1996
Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assayJ R Mascola, M K Louder, S R Surman, et al.
Journal of Virology|April 10, 1999
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodiesJ R Mascola, M G Lewis, G Stiegler, et al.
Pageof 8